Treatment of Castleman’s Disease

Amina Ahmad   by Amina Ahmad, MS, Biotechnology    Last updated on February 12, 2019,

castleman disease treatment

Treating Castleman’s disease

Treatment for Castleman’s disease varies on the basis of its subtypes:

Treatment of unicentric Castleman disease

Localized or unicentric Castleman disease is usually cured with the help of surgery. The diseased-enlarged lymph node (single) can be removed completely. Surgery for unicentric Castleman’s disease can be minor or more extensive depending on a node’s location.

In some cases, if the lymph node is too large, radiation therapy is recommended to shrink it. High-energy ionizing radiations are used during radiotherapy to kill tumor-like cells. Sometimes, corticosteroids are also recommended to reduce the inflammation. Immunotherapy drugs are also recommended to destroy some of the lymph cells.

Treatment of multicentric Castleman disease

Multicentric Castleman’s disease (MCD) is known to affect lymph nodes in several parts of the body. Treating multicentric Castleman’s disease is more challenging if the patient is also suffering from HIV or AIDS. The main aim of MCD treatment is to control the over growth of the cells in the lymph system. Some of the treatment options for multicentric Castleman’s disease are:

Immunotherapy for MCD

Immunotherapy is recommended in MCD as immuno-drugs such as siltuximab (Sylvant) or rituximab (Rituxan) help to inhibit over growth of cells by blocking the action of a protein (interleukin 6 (IL6)) which is produced in high levels in patients of multicentric Castleman’s disease. Excess IL6 can cause lymph cells to grow and divide too quickly. Drugs such as siltuximab have some side effects such as infections, pruritis or itching and maculopapular rash.

Another drug named tocilizumab (Actemra) is also recommended for the treatment of multicentric Castleman’s disease.

Chemotherapy

Chemotherapy is one of the oldest treatment measure used to treat lymph node cancer. Chemotherapy is recommended for patients with severe MCD, with an objective to inhibit the growth of abnormal cells.

In a research published and entitled “Update and new approaches in the treatment of Castleman disease”, low-dose single-agent chemotherapy is found to provides symptom relief but the disease control tends to be lost rapidly after the treatment is over.

Chemotherapy is associated with various side effects, therefore in MCD patients, it is only recommended when a patient does not respond well to immunotherapy or if there are strong chances of having an organ failure.

Drug therapy or other medications


Immunomodulating drugs turn down the immune system as they slow down the growth and activity of T cells or immune cells. Some of such drugs are thalidomide, lenalidomide, cyclosporine, etc.

Some antiviral drugs such as zidovudine, ganciclovir, valganciclovir, etc are recommended for patients to fight viruses such as human herpesvirus-8. HIV-positive patients with multicentric CD are recommended with a slightly different therapeutic intervention. Antiviral therapy is still in the development phase.

In some cases of MCD, a combination of corticosteroids therapy, chemotherapy, immunotherapy, radiation therapy, or antiviral therapy is also recommended. Combinational therapy is also under development phase.

Additional supportive therapy for MCD is autologous bone marrow transplantation. This is an investigational therapy for severe blood related disorders. It is still not proven and scientists are still working on it.

Amina Ahmad

Amina Ahmad is a bio-technologist and aims to deliver a positive contribution in healthcare industry by spreading health awareness in general public. She completed Masters in Technology (Biotechnology) from IMS Engineering College (AKTU). Then, she moved to Jamia Millia Islamia, a technological University in New Delhi, where she worked in the Research Division of Life Sciences Department as a researcher. She was also associated with Advancells, a stem cell company, as a Research Associate and laboratory expert in the past.

 

Currently, Amina is associated with DiseaseFix as a Research Associate and medical content writer. With DiseaseFix, she aspires to educate people about problems associated with their health by helping them understand the disease basics and available treatment options in this new technologically advanced age of the medical arena. Her expertise includes nano-biotechnology, antibacterial benefits of plants, and neglected diseases.


Read More Articles by this Author